Extend Life

Transforming Glaucoma Care

A first-in-class, sustained delivery platform using biodegradable collagen wafers for continuous 24/7 therapeutic release.

A New Standard in Glaucoma Care

80 M people are affected worldwide with glaucoma.¹

20% of patients are compliant with daily eye drops, the current standard of care.²

15% of peak pressures occur outside of waking hours.³

SDD addresses this critical gap with a safe, effective solution that delivers continuous care without the hassle of daily eye drops.

Sustained Drug Delivery’s Latanoprost Implant

SDD has developed a biodegradable collagen-based wafer that delivers continuous, zero-order release of latanoprost directly at the desired site. Implanted in-office through a simple conjunctival incision, the wafer fully dissolves with low risk of inflammation, offering repeatable therapy without the need for surgical intervention.

Our proprietary collagen wafer platform offers several key clinical advantages:

Controlled:

Biodegradable collagen wafers enable sustained, near zero-order release of Latanoprost over six months, eliminating burst release and minimizing variability.

Simple:

Wafers are placed via a small conjunctival incision onto the sclera in a simple, 10-minute procedure.

Improves Adherence:

The platform removes the need for daily eye drops, improving long-term patient compliance and reducing disease progression risk.

Repeatable:

Wafers fully dissolve without causing inflammation, allowing seamless reimplantation every 4–6 months as part of routine care.

Versatile:

Collagen wafers are capable of being adapted to various drop-based treatments for anterior and posterior segment disease.

Company

Sustained Drug Delivery (SDD), a clinical-stage biotechnology company, is developing a next-generation collagen-based drug delivery platform for chronic eye diseases.

SDD is committed to transforming chronic ocular disease treatment through a sustained, repeatable drug delivery implant that provides continuous therapeutic release—eliminating the need for daily drops and improving long-term visual outcomes.